Truvaga (Truvaga Plus / Truvaga 350)

Overview

Truvaga is electroCore’s wellness-positioned consumer brand using the same underlying nVNS technology platform as the FDA-cleared gammaCore Sapphire — founded 2022 in Rockaway NJ as the consumer-accessible alternative to gammaCore’s prescription-only clinical positioning. Two model tiers: Truvaga Plus ($799 unlimited sessions, rechargeable) and Truvaga 350 ($499 fixed 350-session model). Both deliver cervical nVNS via handheld neck-applied stimulation in 2-minute sessions matching gammaCore’s clinical protocol.

The structural value claim is genuine: Truvaga delivers clinical-grade gammaCore engineering at consumer pricing without prescription requirement. For users who want gammaCore’s technology stack (electroCore platform, 2-minute protocol, no gel-pad consumables) but cannot or will not navigate the prescription pathway + ~$598/month cash-pay refill economics, Truvaga is structurally the best alternative.

The structural editorial caveat: Truvaga itself is not FDA-cleared. Despite using the gammaCore platform, Truvaga operates under general-wellness exemption — same regulatory positioning as Pulsetto, Apollo Neuro, and other consumer wellness VNS devices. The platform overlap with gammaCore is real (engineering, waveform, contact surface) but the regulatory positioning is fundamentally different from Truvaga’s wellness-tier marketed indication.

What We Measured

Note: This review is based on Truvaga’s published device specifications, electroCore corporate disclosures linking Truvaga to the gammaCore technology platform, HSA/FSA eligibility documentation via Truemed, Trustpilot review base (~450 reviews at 4.2 aggregate), and aggregated user reports. Hands-on testing of Truvaga Plus is pending.

The gammaCore platform inheritance

This is the structural differentiator. Truvaga uses electroCore’s FDA-cleared gammaCore technology platform:

• Same cervical nVNS targeting (neck stimulation, identical anatomical target)
• Similar waveform characteristics (electroCore’s proprietary stimulation parameters)
• Same 2-minute session protocol (matches gammaCore’s clinical-indication protocol)
• Same built-in contact surface (no gel pads, unlike Pulsetto)

The honest editorial caveat: same platform technology does not equal same clinical evidence. gammaCore’s FDA clearance K211856 is specific to the gammaCore device + migraine/cluster headache indication. Truvaga inherits the engineering platform but does not inherit the clinical evidence base — Truvaga is not FDA-cleared and has not been studied in equivalent clinical trials.

For users who want gammaCore-engineered hardware without prescription requirement, Truvaga is the structurally cheapest pathway to that platform. For users who want the full gammaCore clinical positioning (FDA clearance, RCT evidence, indication-specific use), gammaCore Sapphire is the right tool — at substantially higher cost.

The two-model tier strategy

Truvaga Plus (~$799):

• Unlimited sessions — no usage cap
• Rechargeable hardware
• Multi-year ownership horizon — pays back vs Truvaga 350 within ~12-18 months of regular use

Truvaga 350 (~$499):

• Fixed 350 sessions built into device
• Lower upfront cost — accessible entry tier
• Replacement-cycle economics — at typical 1-2 sessions/day, 350 sessions = 6-12 months
• Better for trial-period buyers uncertain about long-term VNS commitment

For ongoing VNS protocol users, Truvaga Plus is structurally better economics. For trial-period or sub-daily-cadence users, Truvaga 350 is the lower-commitment entry.

The HSA / FSA eligibility

This is meaningful. Truvaga is HSA / FSA eligible via Truemed integration. For users with Health Savings Account or Flexible Spending Account funds, the effective post-tax cost is meaningfully lower (typically 20-30% effective discount depending on tax bracket).

Compare:

• gammaCore: insurance-eligible but limited coverage; HSA/FSA eligible
• Truvaga: HSA/FSA eligible via Truemed
• Pulsetto, Apollo Neuro, Nurosym: typically not HSA/FSA eligible

For HSA/FSA-funded buyers, Truvaga’s effective pricing is meaningfully closer to Pulsetto’s $269 than the headline $499–$799 suggests.

The 2-minute session protocol

Truvaga’s 2-minute protocol matches gammaCore’s clinical positioning. For users wanting workflow-friendly rapid sessions, this is a structural advantage. For users wanting longer cumulative parasympathetic dose (Nurosym’s 30–60 minute approach), Truvaga’s protocol is short.

The honest framing: 2-minute sessions are the clinical-validated gammaCore protocol — there’s a real research-backed reason for the duration. Longer protocols may deliver more dose but lack the same clinical-evidence backing for cervical nVNS specifically.

The not-FDA-cleared positioning despite gammaCore inheritance

This is the central editorial issue. Truvaga’s marketing emphasizes the gammaCore technology connection — legitimately, since the platform inheritance is real. But buyers should understand:

• gammaCore Sapphire has FDA 510(k) clearance K211856 (migraine + cluster headache)
• Truvaga is general-wellness exempt (no specific medical indication)
• Same platform, different regulatory positioning, different marketed indications

For buyers prioritizing FDA clearance as a structural credibility signal, Truvaga’s general-wellness positioning is the wrong tool — gammaCore Sapphire is the right answer despite higher cost. For buyers comfortable with wellness-tier positioning + accessible pricing + gammaCore-platform engineering, Truvaga is structurally the leading consumer-accessible choice.

3-Year Cost of Ownership

Use case	Cost
Truvaga 350 (fixed sessions, replacement at session limit)	$499 → $499 / 6-12 mo cycle
Truvaga Plus (one-time purchase, unlimited use)	~$799
Truvaga Plus + HSA/FSA effective cost (~30% reduction)	~$559 effective
3-year ownership — Truvaga Plus	~$799 ($559 HSA/FSA-effective)

Compare: Pulsetto ($269 + $180 gel pads + optional app sub = ~$449 / 3yr), Apollo Neuro ($349), Nurosym ($729 + replacement electrodes ~$120 / 3yr), gammaCore Sapphire ($21,528 cash 3-year).

Truvaga Plus’s $799 pricing is mid-tier within the consumer VNS market. At HSA/FSA-effective pricing, it’s competitive with Pulsetto’s effective cost. The unlimited-session model + no-consumables operation make it more cost-predictable than alternatives.

Regulatory Status

General-Wellness Exemption (Not FDA-Cleared). Truvaga itself is not FDA-cleared despite using electroCore’s gammaCore technology platform. The gammaCore Sapphire device (separately marketed and prescription-only) carries FDA 510(k) clearance K211856 for migraine and cluster headache — but Truvaga does not inherit this clearance.

When Truvaga Makes Sense — And When It Doesn’t

Strong fit:

• You want gammaCore-platform engineering at consumer pricing without prescription requirement
• You value no gel-pad consumables vs Pulsetto’s recurring replacement costs
• You’re HSA/FSA-funded — effective pricing is meaningfully lower than headline cost
• You want 2-minute clinical-protocol sessions for workflow-friendly daily use
• You’re an established VNS protocol user willing to invest at mid-tier consumer pricing

Weaker fit:

• You want FDA-cleared clinical indication — gammaCore Sapphire is the right tool
• You want lowest-cost VNS entry — Pulsetto is structurally cheaper at $269
• You want longer 30–60 minute deeper-dose sessions — Nurosym is structurally better
• You want multi-program library — Pulsetto’s 5-program approach is more varied
• You’re a trial-period buyer uncertain about long-term VNS commitment — Truvaga 350’s fixed-session model is better fit

Verdict: Recommended

Truvaga earns a recommended verdict on the strength of its gammaCore technology platform inheritance (electroCore’s FDA-cleared engineering at consumer pricing without prescription), no-gel-pad operation eliminating consumable cost vs Pulsetto’s recurring replacement cycle, HSA/FSA eligibility via Truemed providing meaningful effective-cost reduction, 2-minute clinical-protocol sessions matching gammaCore’s research-backed duration, and electroCore’s 20-year multi-decade neurostimulation research portfolio.

For wellness-tier VNS users seeking gammaCore-platform engineering without prescription requirement, Truvaga Plus is structurally the leading mid-tier choice. The combination of platform inheritance + no-consumables + HSA/FSA pathway at $799 ($559 HSA-effective) makes it a defensible upgrade from Pulsetto’s $269 entry-tier.

For buyers seeking FDA-cleared clinical positioning (gammaCore), longest-dose protocols (Nurosym), lowest entry pricing (Pulsetto), or multi-program library variety (Pulsetto), Truvaga is the wrong tool. The wellness-tier positioning + 2-minute protocol + single-program approach limits its appeal to users who specifically want gammaCore’s underlying engineering at consumer accessibility.

Changelog

• 2026-05-06: Initial review published based on Truvaga Plus / Truvaga 350 published device specifications, electroCore platform-inheritance documentation, Trustpilot review aggregation (~450 reviews at 4.2), HSA/FSA eligibility via Truemed, and aggregated user-report data.